

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Rucaparib blocks SARS-CoV-2 virus binding to cells and interleukin-6 release in a model of COVID-19

Henrietta Papp^{1,2,*}, Judit Bóvári-Biri^{3,*}, Krisztina Bánfai^{3,*}, Péter Juhász⁴, Mohamed Mahdi⁵, Lilian Cristina Russo⁶, Dávid Bajusz⁷, Adrienn Sipos^{8,9}, László Petri⁷, Ágnes Kemény^{2,10,11}, Mónika Madai^{1,2}, Anett Kuczmog^{1,2}, Gyula Batta¹², Orsolya Mózner¹³, Dorottya Vaskó¹⁴, Edit Hirsch¹⁴, Péter Bohus¹⁵, Gábor Méhes⁴, József Tózsér⁵, Nicola J. Curtin¹⁶, Zsuzsanna Helyes^{2,10}, Attila Tóth¹⁷, Nicolas C. Hoch⁶, Ferenc Jakab^{1,2}, György M. Keserű⁷, Judit E. Pongrácz², Péter Bai^{8,9,18,19,#}

¹National Laboratory of Virology, University of Pécs, 7624, Pécs, Hungary and Institute of Biology, Faculty of Sciences, University of Pécs, 7624, Pécs, Hungary

²Szentagóthai Research Centre, University of Pécs, 7624, Pécs, Hungary

³Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pécs, 7624, Pécs, Hungary

⁴Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary;

⁵Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032, Hungary;

⁶Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil;

⁷Medicinal Chemistry Research Group, Research Centre for Natural Sciences, 1117, Budapest, Hungary

⁸Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary;

⁹MTA-DE Cell Biology and Signaling Research Group ELKH, Debrecen, 4032, Hungary;

¹⁰Department of Pharmacology and Pharmacotherapy, Medical School; Centre for Neuroscience, 7624, Pécs, Hungary

¹¹Department of Medical Biology, Medical School, Pécs, 7624, Hungary

¹²Department of Organic Chemistry, Faculty of Science and Technology, University of Debrecen, 4032, Debrecen, Hungary

38 ¹³Doctoral School of Molecular Medicine, Semmelweis University, 1094, Budapest,
39 Hungary and Institute of Enzymology, Research Centre for Natural Sciences, 1117,
40 Budapest, Hungary

41 ¹⁴Department of Organic Chemistry and Technology, Faculty of Chemical Technology and
42 Biotechnology, Budapest University of Technology and Economics, 1111, Budapest,
43 Hungary

44 ¹⁵Erzsébet Hospital, Sátoraljaújhely, 3980, Hungary

45 ¹⁶Translational and Clinical Research Institute, Newcastle University Centre for Cancer,
46 Faculty of Medical Sciences, Newcastle University, NE2 4HH, Newcastle upon Tyne, UK

47 ¹⁷Section of Clinical Physiology, Department of Cardiology, University of Debrecen,
48 Debrecen, 4032, Hungary;

49 ¹⁸MTA-DE Lendület Laboratory of Cellular Metabolism, 4032, Debrecen, Hungary;

50 ¹⁹Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen,
51 4032, Debrecen, Hungary;

52 * equal contribution

53

54

55 #Correspondence can be also sent to: Peter Bai, PhD, DSc University of Debrecen, Faculty
56 of Medicine, Department of Medical Chemistry, 4032 Debrecen, Egyetem tér 1., Hungary,
57 Tel. +36 52 412 345; Fax. +36 52 412 566, e-mail: baip@med.unideb.hu

58 **Abstract**

59 Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 virus, is a major global
60 health challenge, as there is no efficient treatment for the moderate to severe disease. ADP-
61 ribosylation events are involved in regulating the life cycle of coronaviruses and the
62 inflammatory reactions of the host, hence we assessed the repurposing of registered PARP
63 inhibitors for the treatment of COVID-19. We detected high levels of oxidative stress and
64 strong PARYlation in all cell types in the lungs of COVID-19 patients. Interestingly, rucaparib,
65 unlike other PARP inhibitors, reduced SARS-CoV-2 infection rate through binding to the
66 conserved 493-498 amino acid region located in the spike-ACE2 interface in the spike
67 protein and prevented viruses from binding to ACE2. In addition, the spike protein-induced
68 overexpression of IL-6, a key cytokine in COVID-19, was inhibited by rucaparib at
69 pharmacologically relevant concentrations. These findings build a case for repurposing
70 rucaparib for treating COVID-19 disease.

71

72

73 **Keywords:**

74 ACE2, ARTD, atypical lung inflammation, cytokine release syndrome, COVID-19, IL6,
75 intermolecular interaction, macrodomain, macrophage overactivation syndrome, NAD+,
76 olaparib, PARP, PARP inhibitor, rucaparib, SARS-COV-2, SARS-COV-2 spike protein,
77 stenoparib, talazoparib, viral lung inflammation

78

79 Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 virus infection, is a
80 global health challenge. SARS-CoV-2 is an enveloped virus with an ssRNA+ genome
81 belonging to the *Coronaviridae* family¹. SARS-CoV-2 predominantly infects the upper airways
82 that may then transfer to lower airways causing atypical lung inflammation¹. The virus uses
83 the angiotensin-converting enzyme 2 (ACE2) as cellular receptor for entry into epithelial
84 cells¹. Although, 80% of the patients develop mild or no symptoms, 15% develop severe
85 disease requiring oxygen support, and 5% develop critical illness. The inflammatory
86 response during the disease strongly contributes to organ damage and critical illness. Severe
87 COVID-19 remains an unmet medical need calling for novel therapeutic modalities.

88 PARPs are ADP-ribosyl transferase enzymes composed of 17 members in humans
89 (PARP1-PARP16)². PARP1, PARP2 and PARP3 can be activated by damaged DNA² that is
90 often the result of reactive oxygen species (ROS) production under inflammatory conditions².
91 PARP activation contributes to necrotic and apoptotic cell death, furthermore, PARP
92 activation has pro-inflammatory properties². Four small molecule pharmacological PARP
93 inhibitors, olaparib, rucaparib, niraparib and talazoparib are FDA/EMA-approved for cancer
94 therapy and fluzoparib and pamiparib are approved by the Chinese NMPA².

95 Poly(ADP-ribosyl)ation (PARylation) of SARS-CoV-2 proteins can limit virus infectivity; a
96 protective measure of the host that can be countered by the virus macrodomain^{3,4}. A recent
97 report suggested that stenoparib, a PARP inhibitor of both classical PARPs and tankyrases,
98 can block the replication of SARS-CoV-2⁵. COVID-19 is characterized by ROS production
99 and PARP activation⁶ that can contribute to cell death and tissue damage². Taken together,
100 PARP inhibition may have a dual pharmacological effect in COVID-19 disease, by blocking
101 both SARS-CoV-2 replication and suppressing the consequent immune reaction. We set out
102 to investigate the opportunity for repurposing registered pharmacological PARP inhibitors for
103 COVID-19.

104 We have observed oxidative stress, marked by 4-hydroxynonenal (4HNE) staining, and
105 PARP activation, marked by PAR immunostaining, in the pneumocytes, endothelial cells and
106 macrophages of the lung tissue of COVID-19 patients (**Fig1A**), highlighting a role for
107 PARylation in COVID-19.

108 Next, we assessed three approved PARP inhibitors, rucaparib, talazoparib and olaparib
109 in a cellular SARS-CoV-2 infection model in concentrations ranging up to 40 μ M. Rucaparib
110 inhibited the infection and proliferation of the B.1.5 variant of SARS-CoV-2 virus (original
111 Wuhan variant with D614G mutation, IC_{50} = 27.5 μ M, **Fig1B**), while talazoparib and olaparib
112 had no effect (**FigS1A**). Importantly, rucaparib was not toxic at concentrations that
113 profoundly inhibited viral proliferation (the IC_{50} value for toxicity was 64.8 μ M **Fig1B**), hence,
114 it is not direct toxicity that limits SARS-CoV-2 infection and proliferation.

115 The IC₅₀ concentration for viral infection of rucaparib (27.5 µM corresponding to ~8.7
116 mg/L) is much higher than that achieved at the recommended dose (600 mg BID, steady
117 state level ~2.4 mg/l⁷), furthermore, PARP inhibition of >90% is achieved using doses of 92
118 mg⁸. Therefore the impact on viral replication is unlikely to be due to PARP1 inhibition and
119 may result from binding to other targets e.g. the spike protein. We tested this hypothesis in
120 neutralization experiments. Rucaparib was preincubated with a pseudovirus bearing the
121 spike protein of SARS-CoV-2 (wild-type, delta and the omicron variants) or the SARS-CoV-2
122 virus (alpha variant) and it inhibited virus uptake of all major variants of SARS-CoV-2 (**Fig.**
123 **1C-D**), suggesting that rucaparib abrogates the binding of the virus to host cell receptors.
124 Rucaparib bound directly to the spike protein of SARS-CoV-2 (IC₅₀ = 115±21.9 µM) in an *in*
125 *vitro* assay, while no significant binding was detected for the other PARP inhibitors
126 stenoparib and olaparib at concentrations up to 500 µM (**Fig. 2A**). We observed
127 magnetisation transfer from the receptor-binding domain (RBD) of spike to rucaparib in
128 saturation difference spectrum NMR (STD-NMR) experiments that verifies rucaparib binding
129 to the RBD *in vitro* (**Fig2B**).

130 Next, we identified the putative binding site of rucaparib. A single binding hotspot was
131 identified at the protein-protein interaction surface of all three variants (**FigS1B**),
132 characterized by the residues 493-498, with further sidechains R403, E406, Y449, Y453,
133 N501 and Y505 in the vicinity (**Fig2C**). The predicted binding mode of rucaparib is stabilized
134 mainly by a strong ionic interaction between the negatively charged E406 sidechain and the
135 terminal methylamine group of rucaparib. The latter is a positively charged and highly flexible
136 moiety that is exclusive to this compound among the four PARP inhibitors tested in this
137 study, which is in line with the exclusive on-target affinity of rucaparib. Additional interactions
138 involve an H-bond between N501 and the NH group of the lactam unit, and back-to-back
139 cation-pi interactions between Y453 and the methylamine group, as well as R403 and the
140 phenyl ring. The STD-NMR shows magnetisation transfer (**Fig2B**) from RBD to H15, H16,
141 H18 and H19 of the aromatic moiety of rucaparib that verifies binding and the validity of the
142 *in silico* docking (**Fig2C, FigS1B**). Most amino acids responsible for rucaparib binding were
143 conserved among SARS-CoV-2 variants. The omicron variant harbored the highest number
144 of mutations at the binding site (**Fig2D**).

145 We assessed whether rucaparib targets the macrodomain of SARS-CoV-2 by applying a
146 previously described model³. In agreement with previous results, Interferon-γ (IFNγ)
147 treatment induced substantial cellular ADP-ribosylation that was reduced by ~50% when the
148 macrodomain of SARS-CoV-2 was overexpressed³. Rucaparib treatment at either 500 nM or
149 20 µM did not prevent this macrodomain-dependent reduction in IFN-induced ADP-
150 ribosylation relative to control cells (**FigS1C**), suggesting that rucaparib does not inhibit the

151 viral macrodomain at the concentrations tested. However, we observed a concentration-
152 dependent effect of rucaparib on the overall induction of ADP-ribosylation by IFN- γ (**FigS1C**).

153 Next, we assessed the capacity of rucaparib to inhibit the expression of interleukin-6 (IL-
154 6); a central cytokine in COVID-19¹. In human macrophages, challenged by bacterial
155 lipopolysaccharide (LPS), 20 μ M rucaparib significantly reduced the expression of IL6, IL8
156 and IL10 at a similar or better efficacy as dexamethasone (**Fig2E, FigS2A**). Talazoparib (10
157 μ M) and olaparib (20 μ M) had no effect in this regard (data not shown). Subsequently, we
158 induced IL-6 expression in macrophages with SARS-CoV-2 spike protein, and in this system
159 rucaparib also blocked IL-6 overexpression (**Fig2F**) without affecting IL-1 β and TNF α
160 expression (data not shown). Finally, we assessed members of the Signal Transducer and
161 Activator of Transcription (Stat) family of transcription factors (Stat1, 3, 5A, 5B), which are
162 key mediators of interferon signaling and were implicated in COVID-19⁹. Stat1 and Stat3
163 were activated upon poly(I:C) or spike induction that was not inhibited rucaparib at
164 pharmacologically relevant concentrations (**FigS2B, C**). Interestingly, Stat5A and 5B
165 activation was inhibited by spike, however, no statistically significant changes to Stat5A and
166 5B were elicited by rucaparib treatment (**FigS2C**).

167 We showed that rucaparib can bind to the spike protein of SARS-CoV-2 and, therefore
168 inhibit the binding of SARS-CoV-2 to the ACE2 receptor and virus entry into host cells. These
169 findings are similar to the reports on stenoparib that can inhibit SARS-CoV-2 proliferation in
170 low concentrations⁵. Interestingly, olaparib and talazoparib had no effect on SARS-CoV-2
171 infection and proliferation. Most amino acids responsible for rucaparib binding are conserved
172 among variants pointing out that rucaparib can be repurposed to block SARS-CoV-2 binding.
173 Furthermore, the rucaparib binding site is a potential site for drug development to target the
174 SARS-CoV-2 – ACE2 interaction.

175 Another important, and clinically relevant finding of the study is that rucaparib can
176 efficiently block the expression of IL-6, the key interleukin involved in COVID-19-related
177 inflammatory response¹. In human monocyte-derived macrophages, rucaparib blunted both
178 LPS or SARS-CoV-2 spike protein induced IL-6 overexpression. The lower rucaparib
179 concentrations are pharmacologically relevant and are comparable to the achievable serum
180 levels of rucaparib in humans^{7,10}.

181 In the frame of this study, we assessed the applicability of pharmacological PARP
182 inhibition in COVID-19 disease. We detected oxidative stress and PARylation in the lungs of
183 COVID-19 patients similar to previous reports⁶. A large set of studies have provided evidence
184 that PARP(1) activation is proinflammatory². Several aspects of PARP-mediated
185 inflammatory response have direct relevance to COVID-19-related inflammatory lung injury.
186 Genetic or pharmacological PARP inhibition was protective in asthma, acute lung injury
187 (burn, smoke inhalation, bacterial infection, etc.), ARDS, chronic obstructive pulmonary

188 disease (COPD), lung fibrosis or ventilation-induced lung injury (reviewed in ¹¹). Importantly,
189 an overwhelming set of data point out that these findings can be translated to the human
190 situation, for example, treatment with INO-1001; a PARP inhibitor, reduced serum IL-6
191 expression in humans¹². The immunosuppressive effects of PARP inhibition in humans is
192 further supported by a report¹³ showing that patients receiving PARP inhibitors as
193 oncological treatment produced fewer neutralizing antibodies following SARS-CoV-2
194 vaccination as healthy volunteers.

195 Of note, there are other PARP-related events, relevant to COVID-19, which were not
196 tested in our study. PARP overactivation can contribute to cell death and tissue damage^{2,11}.
197 Furthermore, PARP activation can strongly reduce cellular NAD⁺ levels² that was implicated
198 in the pathogenesis of COVID-19⁶. Several members of the PARP family, such as PARP9,
199 PARP11 and PARP14 were also implicated in antiviral protection, including SARS-CoV-2^{3,14-}
200 ¹⁸, often acting in different steps within the IFN signaling cascade. High doses of rucaparib
201 may interfere with these PARP enzymes, as high dose rucaparib impaired IFN-induced ADP-
202 ribosylation.

203 Taken together, rucaparib has a dual action in COVID-19, it can disrupt the binding of
204 SARS-CoV-2 to ACE2 and it can target the inflammatory response. Although, the IC₅₀ value
205 of rucaparib in disrupting the SARS-CoV-2 binding is higher than the steady state levels on
206 the dose approved for cancer therapy, rucaparib could potentially be applied as an aerosol in
207 patients to achieve higher local concentrations so rucaparib can exert its dual effects in the
208 lungs. Rucaparib, unlike the other clinically approved PARP inhibitors, was reported to
209 continue to inhibit PARP1 for extended periods even after its removal^{19,20}, further
210 strengthening the case of its repurposing. Of note, the anti-inflammatory potential of
211 rucaparib was comparable to dexamethasone, the standard of care in COVID-19, in the
212 models used in this study. PARP inhibitors can potentially be synergistic with tocilizumab,
213 and anti-IL-6 monoclonal antibody used against the cytokine storm, as well as with the anti-
214 inflammatory drugs used in the therapy of COVID-19. These observations point towards the
215 repurposing of rucaparib to combat COVID-19.

216

217 **Acknowledgement**

218 The work was supported by grants from the NKFIH (K132623, K123975, K135150, K141142,
219 TKP2021-EGA-10, TKP-2021-EGA-13, TKP2021-EGA-19, TKP2021-EGA-20, TKP2021-
220 NVA-07). The Projects no. TKP2021-EGA-10, TKP-2021-EGA-13, TKP2021-EGA-19,
221 TKP2021-EGA-20 were implemented with the support provided from the National Research,
222 Development and Innovation Fund of Hungary, financed under the TKP2021-EGA funding
223 scheme. Project no. TKP2021-NVA-07 has been implemented with the support provided
224 from the National Research, Development and Innovation Fund of Hungary, financed under
225 the TKP2021-NVA funding scheme. The POST-COVID2021-33 grant to PB was from the
226 Hungarian Academy of Sciences. FAPESP grants 2018/18007-5 and 2020/05317-6 were to
227 NH. The research was performed in collaboration with Cell and Tissue Culture Core
228 Facility at the Szentagothai Research Centre of the University of Pecs. The work of D.B. was
229 supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences
230 and the UNKP- 21-5 New National Excellence Program of the Ministry for Innovation and
231 Technology. Prepared with the professional support of the Doctoral Student Scholarship
232 Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology
233 financed from the National Research, Development and Innovation Fund (to OM). The
234 authors are grateful to Dr. Balazs Sarkadi (Institute of Enzymology, Research Centre for
235 Natural Sciences, Budapest, Hungary) for his support and the critical revision of the
236 manuscript.

237

238 **Conflict of interest**

239 Rucaparib was a generous gift from Clovis Oncology (Boulder, CO, USA). Clovis had no
240 impact on study design and the conclusions drawn.

241 Dr. Curtin is an inventor on patents WO 2005/012305 A2 and WO/2006/033006 with royalties
242 paid to CRUK and Newcastle University, she gives her royalty share to charity and took no
243 royalty in relation to this study.

244 Other authors declare no conflict of interest.

245

246 **Data availability**

247 Primary data is available at <https://figshare.com/s/6b25fd3d5de80ab3f51e> (DOI:
248 10.6084/m9.figshare.19418957).

249 **Figure captions**

250 **Figure 1. Rucaparib inhibits the binding of SARS-CoV-2 to the host cell**

251 **(A)** In lungs of controls and patients died of COVID-19 SARS-CoV-2 spike protein, 4-
252 hydroxynonenal and poly(ADP-ribose) immunohistochemistry was performed and evaluated.
253 **(B)** The antiproliferative and toxic effects of rucaparib were tested on Vero E6 cells infected
254 with of B.1.5 variant SARS-CoV-2. **(C)** Fluorescently-labelled pseudovirions were pre-treated
255 with 35 μ M rucaparib and pseudovirus uptake was assessed in HEK293T cells. **(D)** The
256 alpha variant of SARS-CoV-2 was pretreated with rucaparib and was used to infect Vero E6
257 cells.

258

259 **Figure 2. Rucaparib binds to the spike protein of SARS-CoV-2, and effectively inhibits**
260 **IL-6 expression**

261 **(A)** The indicated PARP inhibitors were tested to block the spike-ACE2 interaction in an *in*
262 *vitro* binding assay. **(B)** STD-NMR spectrum of rucaparib alone and in complex with the
263 receptor-binding domain of spike. **(C)** Predicted binding mode of rucaparib (green) at the
264 protein-protein binding surface of the SARS-CoV2 RBD (fawn), with the main protein-ligand
265 interactions highlighted as dashed lines (magenta: ionic interaction, yellow: H-bond, green:
266 cation- π interaction). **(D)** The sequence of the rucaparib binding site from the available
267 variants were compared. **(E-F)** Human primary monocytes differentiated to macrophages
268 were treated as indicated and IL-6 production was measured.

269 **References**

- 270 1. Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. & Di Napoli, R. in *StatPearls*
271 (StatPearls Publishing, Treasure Island (FL), 2022).
- 272 2. Curtin, N.J. & Szabo, C. *Nature Reviews Drug Discovery* **19**, 711-736 (2020).
- 273 3. Russo, L.C., et al. *Journal of Biological Chemistry* **297**, 101041 (2021).
- 274 4. Fehr, A.R., et al. *Genes and Development* **34**, 341-359 (2020).
- 275 5. Zarn, K.E., et al. *BioRxiv*, <https://doi.org/10.1101/2021.1111.1103.467186> (2021).
- 276 6. Heer, C.D., et al. *Journal of Biological Chemistry* **295**, 17986-17996 (2020).
- 277 7. Shapiro, G.I., et al. *Clin Pharmacol Drug Dev* **8**, 107-118 (2019).
- 278 8. Drew, Y., et al. *Br J Cancer* **114**, 723-730 (2016).
- 279 9. Luo, W., et al. *Trends in Pharmacological Sciences* **41**, 531-543 (2020).
- 280 10. Wilson, R.H., et al. *British Journal of Cancer* **116**, 884-892 (2017).
- 281 11. Curtin, N., et al. *British Journal of Pharmacology* **177**, 3635-3645 (2020).
- 282 12. Morrow, D.A., et al. *Journal of Thrombosis and Thrombolysis* **27**, 359-364 (2009).
- 283 13. Liontos, M., et al. *Vaccines* **9**(2021).
- 284 14. Caprara, G., et al. *Journal of immunology (Baltimore, Md. : 1950)* **200**, 2439-2454
285 (2018).
- 286 15. Daugherty, M.D., Young, J.M., Kerns, J.A. & Malik, H.S. *PLoS Genetetics* **10**,
287 e1004403. (2014).
- 288 16. Xing, J., et al. *Nature Communications* **12**, 2681 (2021).
- 289 17. Guo, T., et al. *Nature microbiology* **4**, 1872-1884 (2019).
- 290 18. Tauber, A.L., Schweiker, S.S. & Levonis, S.M. *Future Medicinal Chemistry* **13**, 587-
291 592 (2021).
- 292 19. Smith, H.L., Willmore, E., Mukhopadhyay, A., Drew, Y. & Curtin, N.J. *bioRxiv*,
293 2022.2001.2024.477471 (2022).
- 294 20. Murray, J., et al. *Br J Cancer* **110**, 1977-1984 (2014).

295





Figure 1.

